Itraconazole: An update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 7, 2013, Pages 911-926

  Lestner, Jodi ^a   Hope, William W ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antifungal; Itraconazole; Pharmacodynamics; Pharmacokinetics; Toxicodynamics

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUDESONIDE; CARBAMAZEPINE; DEXAMETHASONE; DIGOXIN; FLUTICASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; METHYLPREDNISOLONE; PHENYTOIN; RIFAMPICIN; VINCRISTINE; VORICONAZOLE; WARFARIN;

ALLERGIC FUNGAL INFECTION; ALOPECIA; ANEMIA; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; BLASTOMYCOSIS; CANDIDA ALBICANS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCUS NEOFORMANS; DERMATOPHYTOSIS; DIAPHORESIS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG STRUCTURE; DYSPNEA; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIRSUTISM; HISTOPLASMOSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LEUKOPENIA; LIMB WEAKNESS; LUNG ASPERGILLOSIS; MENSTRUATION DISORDER; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; OROPHARYNX CANDIDIASIS; PENICILLIUM MARNEFFEI; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHOTOSENSITIVITY; POLYURIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SPOROTRICHOSIS; STEVENS JOHNSON SYNDROME; SYSTEMIC MYCOSIS; TASTE DISORDER; THROMBOCYTOPENIA; THYROID DISEASE; TINNITUS; TREMOR; VISUAL DISORDER;

ABSORPTION; ANTIFUNGAL AGENTS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84879237440     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.794785     Document Type: Article

References (135)

1. Van Cutsem J, Van Gerven F, Van De Ven MA, et al. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 1984;26:527-34 (Pubitemid 14018091)
2. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15 (Pubitemid 26304513)
3. Caillot D, Bassaris H, Mcgeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-90
4. Kreisel W. Therapy of invasive aspergillosis with itraconazole: our own experiences and review of the literature. Mycoses 1994;37(Suppl 2):42-51
5. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990;112:108-12 (Pubitemid 20022690)
6. Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:658-61
7. Mcginnis MR, Nordoff N, Li RK, et al. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol 2001;39:369-71 (Pubitemid 32791487)
8. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med 1993;95:279-85 (Pubitemid 23270285)
9. Sharkey-Mathis PK, Velez J, Fetchick R, Graybill JR. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J Acquir Immune Defic Syndr 1993;6:809-19 (Pubitemid 23183354)
10. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992;93:489-97
11. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008;46:1801-12
12. Graybill JR, Stevens DA, Galgiani JN, et al. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med 1990;89:282-90 (Pubitemid 20323253)
13. Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thai 1992;75:688-91 (Pubitemid 23269947)
14. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001;35:720-9 (Pubitemid 32523607)
15. Frijlink HW, Eissens AC, Hefting NR, et al. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm Res 1991;8:9-16
16. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol 1976;83:367-82
17. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998;42:1862-5. (Pubitemid 28311595)
18. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997;50:477-80 (Pubitemid 27315993)
19. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615-26. (Pubitemid 46594036)
20. Boogaerts MA, Maertens J, Van Der Geest R, et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 2001;45:981-5. (Pubitemid 32182062)
21. Wang J, Huang G. Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution. Drug Deliv 2011;18:631-8
22. Chen W, Gu B, Wang H, et al. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm 2008;362:133-40
23. Bradford CR, Prentice AG, Warnock DW, Copplestone JA. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother 1991;28:555-60
24. Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents 2007;30:93-4 (Pubitemid 46876756)
25. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80 (Pubitemid 30122116)
26. Sanati H, Belanger P, Fratti R, GHannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-6 (Pubitemid 27467562)
27. Lamb DC, Kelly DE, Venkateswarlu K, et al. Generation of a complete, soluble, and catalytically active sterol 14 alpha-demethylase-reductase complex. Biochemistry 1999;38:8733-8
28. Ji H, Zhang W, Zhou Y, et al. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 2000;43:2493-505 (Pubitemid 30437131)
29. Sheng C, Miao Z, JI H, et al. Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding. Antimicrob Agents Chemother 2009;53:3487-95
30. Sheng C, Zhang W, Zhang M, et al. Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions. J Biomol Struct Dyn 2004;22:91-9 (Pubitemid 39095286)
31. Fraczek MG, Bromley M, Bowyer P. An improved model of the Aspergillus fumigatus CYP51A protein. Antimicrob Agents Chemother 2011;55:2483-6
32. Warrilow AG, Martel CM, Parker JE, et al. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 2010;54:4235-45
33. Mercer EI. Inhibition of sterol 14 alpha-demethylase enzymes. Biochem Soc Trans 1983;11:663-5
34. Hitchcock CA, Dickinson K, Brown SB, et al. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. Biochem J 1990;266:475-80 (Pubitemid 20090149)
35. Buied A, Moore CB, Denning DW, Bowyer P. High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J Antimicrob Chemother 2013;68(3):512-14
36. Mortensen KL, Mellado E, Lass-Florl C, et al. Environmental study of azole-resistant Aspergillus fumigatus and other Aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 2010;54:4545-9
37. Camps SM, Van Der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012;56:10-16
38. Yan L, Li M, Cao Y, et al. The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility. J Antimicrob Chemother 2009;64:764-73
39. Bowyer P, Mosquera J, Anderson M, et al. Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus. FEMS Microbiol Lett 2012;332:10-19
40. Vale-Silva LA, Coste AT, Ischer F, et al. Azole resistance by loss of function of the sterol Delta(5),(6)-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob Agents Chemother 2012;56:1960-8
41. Martel CM, Parker JE, Bader O, et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother 2010;54:3578-83
42. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1364-8 (Pubitemid 27231443)
43. Snelders E, Van Der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008;5:e219
44. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011;52:1123-9
45. Dannaoui E, Borel E, Monier MF, et al. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001;47:333-40 (Pubitemid 32229575)
46. Chen J, Li H, Li R, et al. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 2005;55:31-7 (Pubitemid 40192611)
47. Chowdhary A, Kathuria S, Xu J, et al. Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR(3)(4)/L98H mutations in the cyp51A gene in India. PLoS One 2012;7:e52871
48. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole. Scand J Infect Dis 1997;29:509-12
49. Lockhart SR, Frade JP, Etienne KA, et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011;55:4465-8
50. Snelders E, Huis In 't, Veld RA, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009;75:4053-7
51. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15:1068-76
52. Tashiro M, Izumikawa K, Minematsu A, et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 2012;56:584-7
53. Chowdhary A, Kathuria S, Randhawa HS, et al. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012;67:362-6
54. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008;46:2568-72
55. Arendrup MC, Cuenca-Estrella M, Lass-Florl Chope WW. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012;18:E248-50
56. Arendrup MC, Jensen RH, Grif K, et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis 2012;206:981-5
57. Liu W, Sun Y, Chen W, et al. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother 2012;56:2598-603
58. Al-Nakeeb Z, Sudan A, Jeans AR, et al. Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole resistant infection and utility of airway administration. Antimicrob Agents Chemother 2012;56(8):4146-53
59. Conway SP, Etherington C, Peckham DG, et al. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. J Antimicrob Chemother 2004;53:841-7 (Pubitemid 38660289)
60. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-13
61. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-84. (Pubitemid 23096878)
62. Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006;45:1099-114 (Pubitemid 44631389)
63. Hennig S, Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007;63:438-50 (Pubitemid 46426628)
64. Koks CH, Huitema AD, Kroon ED, et al. Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Ther Drug Monit 2003;25:229-33 (Pubitemid 36373432)
65. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997;52:235-7 (Pubitemid 27278380)
66. Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994;46:147-50 (Pubitemid 24101333)
67. Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998;18:295-301. (Pubitemid 28145146)
68. Kunze KL, Nelson WL, Kharasch ED, et al. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 2006;34:583-90
69. Poirier J, Mcheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35:461-73 (Pubitemid 29010176)
70. Savani DV, Perfect JR, Cobo L, Mdurack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987;31:6-10 (Pubitemid 17212647)
71. Perfect J, Rdurack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother 1985;16:81-6 (Pubitemid 15002354)
72. Kamberi P, Sobel RA, Clemons KV, et al. Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob Agents Chemother 2007;51:998-1003 (Pubitemid 46355286)
73. Sorensen KN, Sobel RA, Clemons KV, et al. Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. Antimicrob Agents Chemother 2000;44:1512-17 (Pubitemid 30340787)
74. Haynes RR, Connolly PA, Durkin MM, et al. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis 2002;185:1830-2 (Pubitemid 34615483)
75. Sobue S, Sekiguchi K, Nabeshima T. Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother 2004;48:216-23 (Pubitemid 38040200)
76. Van Cauteren H, Heykants J, Coster DE, Rcauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987;9(Suppl 1):S43-6
77. Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob Agents Chemother 2004;48:3823-7 (Pubitemid 39304610)
78. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74
79. Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2012;55:290-7
80. Yuan R, Flockhart D, Abalian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999;39:1109-25 (Pubitemid 30644013)
81. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997;19:609-13 (Pubitemid 28046984)
82. Dong J, Yu X, Wang L, et al. Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats. Acta Pharmacol Sin 2008;29:1247-52
83. Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 2009;53:3549-51
84. Andrade RA, Evans RT, Hamill RJ, et al. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis. Ann Pharmacother 2009;43:908-13
85. Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis 2007;45:e77-9
86. Crommentuyn KM, Mulder JW, Sparidans RW, et al. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin Infect Dis 2004;38:e73-5
87. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001;51:443-50 (Pubitemid 32852982)
88. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000;56:57-60 (Pubitemid 30317782)
89. Parmar JS, Howell T, Kelly J, Bilton D. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 2002;57:749-50 (Pubitemid 34864536)
90. Skov M, Main KM, Sillesen IB, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002;20:127-33 (Pubitemid 34822934)
91. Berenguer J, Ali NM, Allende MC, et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994;38:1303-8. (Pubitemid 24170711)
92. Law D, Moore CB, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 1994;38:1561-6 (Pubitemid 24203569)
93. Odds FC, Dupont B, Rinaldi MG, et al. Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother 1999;43:723-7 (Pubitemid 29231702)
94. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32(Suppl 1):103-8 (Pubitemid 20118620)
95. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999;42:443-51 (Pubitemid 29470385)
96. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994;97:135-44. (Pubitemid 24250673)
97. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47 (Pubitemid 127774263)
98. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13 .
99. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood. 2004;103:1527-33. (Pubitemid 38168674)
100. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-9 (Pubitemid 38168678)
101. Takahashi N, Kameoka Y, Yamanaka Y, et al. Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Intern Med 2008;47:651-3 (Pubitemid 351936258)
102. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011;46:709-18
103. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011;52:e56-93
104. Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010;51:1383-91
105. Tsubura E. Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group. Kekkaku 1997;72:557-64 (Pubitemid 27505474)
106. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998;37:303-8 (Pubitemid 28189696)
107. Hanifin JM, Tofte SJ. Itraconazole therapy for recalcitrant dermatophyte infections. J Am Acad Dermatol 1988;18:1077-80
108. Saul A, Bonifaz A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 1990;23:554-8 (Pubitemid 20263678)
109. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
110. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:1255-65 (Pubitemid 351411897)
111. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:807-25 (Pubitemid 47580372)
112. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-23 (Pubitemid 41532662)
113. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002;34:277-84 (Pubitemid 34028362)
114. Denning DW, Tucker RM, Hanson LH, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301-8 (Pubitemid 19258176)
115. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:291-6
116. Van Der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21 (Pubitemid 27290842)
117. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322
118. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America MMWR. Recomm Rep 2009;58:1-207; quiz CE1-4
119. Smith D, Van DE Velde V, Woestenborghs R, Gazzard BG. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992;44:618-19
120. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial FAST; study. Am J Respir Crit Care Med 2009;179:11-18.
121. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-62 (Pubitemid 30151919)
122. Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother 2007;51:2668-73 (Pubitemid 47206198)
123. De Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998;42:404-8 (Pubitemid 28114453)
124. Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002;46:2554-63 (Pubitemid 34793463)
125. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999;24:1089-93
126. Boelaert J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988;32:1595-7
127. Heykants J, Van Peer A, Van De Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(Suppl 1):67-87
128. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009;49:928-30
129. Fung SL, Chau CH, Yew WW. Cardiovascular adverse effects during itraconazole therapy. Eur Respir J 2008;32:240
130. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-7 (Pubitemid 32524211)
131. Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, et al. Hepatic injury associated with itraconazole. Lancet 1992;340:251-2
132. Baxter CG, Marshall A, Roberts M, et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother 2011;66:2136-9
133. Ruiz-Contreras J, Rodriguez R, Gomez DE, et al. Severe hypokalemia and rhabdomyolysis associated with itraconazole therapy. Pediatr Infect Dis J 2003;22:1024-5 (Pubitemid 37445087)
134. Warnock DW, Turner A, Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 1988;21:93-100
135. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;21:580-6